Skip to main content
Clinical Trials/NCT03979586
NCT03979586
Completed
Not Applicable

Intradermal Delivery of Fractional CO2 Laser-assisted Hyaluronic Acid in Facial Skin Remodeling

Assistance Publique Hopitaux De Marseille1 site in 1 country20 target enrollmentStarted: September 17, 2019Last updated:

Overview

Phase
Not Applicable
Status
Completed
Enrollment
20
Locations
1
Primary Endpoint
Measurement of the improvment of one of the skin remodeling parameters (cutaneous texture, firmness, fine lines, radiance) using a scale from 0 to 10

Overview

Brief Summary

The main endpoint will be to evaluate the efficacy of laser-assisted hyaluronic acid delivery by fractional CO2 laser in facial skin remodeling. The secondary endpoint will be to confirm the safety of this protocol compared to a standard treatment by fractional CO2 laser.

Detailed Description

Fractional CO2 lasers are already used in skin remodeling. They can also create vertical channels to enhance topical drug delivery deep into the dermis. Combining the efficacy of fractional CO2 laser to laser-assisted hyaluronic acid delivery has not yet being studied, the combination of these two techniques could improve facial skin remodeling.

The main endpoint will be to evaluate the efficacy of laser-assisted hyaluronic acid delivery by fractional CO2 laser in facial skin remodeling. The secondary endpoint will be to confirm the safety of this protocol compared to a standard treatment by fractional CO2 laser.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
30 Years to 70 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients admitted to the Laser Center for facial skin remodeling,
  • aged from 30 to 70 years old,
  • with phototype I to IV (Fitzpatrick scale),
  • agreeing to participate in this study, signing the informed consent form
  • not fitting in any non-inclusion criterion

Exclusion Criteria

  • Pregnancy or breastfeeding,
  • active infection, history of oral or genital herpes
  • suspected neoplasia,
  • active inflammatory or infectious facial dermatitis,
  • oral retinoid treatment in the last 6 months,
  • phototype V or VI (Fitzpatrick scale)
  • age \<30 years or\> 70 years,
  • patients under guardianship or curatorship,
  • hemostasis disorders, thrombolytic or anticoagulant therapy, c
  • ongenital methaemoglobinaemia,

Outcomes

Primary Outcomes

Measurement of the improvment of one of the skin remodeling parameters (cutaneous texture, firmness, fine lines, radiance) using a scale from 0 to 10

Time Frame: 3 months

The primary judgment criterion will be the improvement at 3 months of at least one of the skin remodeling parameters (cutaneous texture, firmness, fine lines, radiance) at least 2 points greater (on a scale of 0 to 10) on fractional laser and hyaluronic acid-treated hemiface compared to fractional laser and control saline-treated hemiface.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials